Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | E7449 |
Synonyms | |
Therapy Description |
E7449 binds to and inhibits PARP1 and PARP2, as well as TNKS1 and TNKS2, potentially resulting in increased sensitivity to DNA damaging agents and decreased growth of tumor cells with defective DNA damage repair (PMID: 26513298). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
E7449 | 2X-121 | PARP Inhibitor (Pan) 21 Tankyrase Inhibitor 10 | E7449 (2X-121) binds to and inhibits PARP1 and PARP2, as well as TNKS1 and TNKS2, potentially resulting in increased sensitivity to DNA damaging agents and decreased growth of tumor cells with defective DNA damage repair (PMID: 26513298, PMID: 32523090). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATRX inact mut | Advanced Solid Tumor | sensitive | E7449 | Preclinical | Actionable | In a preclinical study, E7449 inhibited proliferation of a ATRX-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298). | 26513298 |
Unknown unknown | ovarian cancer | not applicable | E7449 | Phase I | Actionable | In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells and resulted in partial response in 40% (2/5) of the patients with ovarian cancer (J Clin Oncol 36, 2018 (suppl; abstr 2505); abstr e19531; NCT01618136). | detail... |
Unknown unknown | pancreatic cancer | not applicable | E7449 | Phase I | Actionable | In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells and resulted in stable disease for more than 24 weeks in 7 patients with pancreatic cancer (J Clin Oncol 36, 2018 (suppl; abstr 2505); abstr e19531; NCT01618136). | detail... |
ATM inact mut | Advanced Solid Tumor | sensitive | E7449 | Preclinical | Actionable | In a preclinical study, E7449 inhibited proliferation of a ATM-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298). | 26513298 |
Unknown unknown | Advanced Solid Tumor | not applicable | E7449 | Phase I | Actionable | In a Phase I trial, E7449 treatment demonstrated safety and resulted in an overall response rate of 4.9% (2/41, partial responses) and stable disease in 31.7% (13/41) of patients with advanced solid tumors, including stable disease lasting greater than 23 weeks in 8 patients (PMID: 32523090; NCT01618136). | 32523090 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03878849 | Phase II | E7449 | Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP (PREDICT 2X-121) | Recruiting | USA | 0 |